Breaking News

Merck KGaA, Maker of Erbitux Cancer Drug, to Acquire Sigma-Aldrich for $17 Billion
Tweet TWEET

PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting

PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor
                       Vlla At 2012 ASH Annual Meeting

PR Newswire

ATLANTA and NES-ZIONA, Israel, Dec. 7, 2012

ATLANTA and NES-ZIONA, Israel, Dec. 7, 2012 /PRNewswire/ --PROLOR Biotech,
Inc. (NYSE MKT: PBTH), today announced that the company will present
preclinical data on its long-acting clotting Factor VIIa (Factor Vlla-CTP) at
the 54th Annual Meeting of the American Society of Hematology (ASH). The data
will be discussed by Dr. Gili Hart, Director of Pre-Clinical Affairs at PROLOR
and head of the company's long-acting clotting factors program, in an oral
poster presentation on December 8, 2012. PROLOR's Factor VIIa-CTP is in
advanced preclinical development for the treatment of hemophilia.

Top-line results of the Factor Vlla-CTP studies have been previously reported
by PROLOR. The results show that when compared to commercially available
Factor VIIa, Factor VIIa-CTP in hemophilic mice demonstrated a markedly
enhanced pharmacokinetic profile and increased exposure, as evidenced by a
prolonged hemostatic effect and improved recovery, which is a measure of
clotting activity. Compared to commercially available Factor VIIa, Factor
VIIa-CTP in hemophilic mice demonstrated superior thrombin generation
parameters, and it resulted in greater survival of the subjects. In these
studies, the specific activity of Factor VIIa-CTP was comparable to commercial
Factor VIIa. The study data also show that administration of Factor Vlla-CTP
by subcutaneous injection resulted in improved bioavailability and prolonged
exposure compared to intravenous administration of Factor Vlla-CTP.

PROLOR CEO Dr. Abraham Havron commented, "The ASH Annual Meeting is the
largest and most prominent gathering of hematology experts in the world. In
preclinical studies our long-acting clotting factors have demonstrated the
potential to significantly improve both the prophylactic and on-demand
treatment of patients with hemophilia, and we welcome the opportunity to share
these promising data with leading hematology researchers."

Dr. Hart will present PROLOR's poster, "Factor VIIa-CTP,a Novel Long-Acting
Coagulation Factor with Enhanced Long Term Haemostatic Effect and Improved
Pharmacokinetics and Pharmacodynamic Properties Following IV Administration in
Hemophilic Animal Models," on December 8, 2012 at 5.30 pm EST. The 2012 ASH
Annual Meeting is being held December 8-11, 2012 in Atlanta, Georgia. For
more information, visit www.hematology.org/Meetings/Annual-Meeting/.

ABOUT PROLOR
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying
unique technologies, including patented CTP technology and its long-acting
reversible-pegylation technology, primarily to develop longer-acting
proprietary versions of already approved therapeutic proteins that currently
generate billions of dollars in annual global sales. The CTP technology is
applicable to virtually all proteins. PROLOR is developing a long-acting
version of human growth hormone, which successfully completed a Phase II
clinical trial. It also is developing long-acting versions of Factor VIIa and
Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide
for diabetes and obesity, all of which are in preclinical development. For
more information, visit www.prolor-biotech.com.

Safe Harbor Statement: This press release contains forward-looking
statements, which may be identified by words such as "expects," "plans,"
"projects," "will," "may," "anticipates," "believes," "should," "would",
"intends," "estimates," "suggests," "has the potential to" and other words of
similar meaning, including statements regarding the results of current
clinical studies and preclinical experiments and the effectiveness of PROLOR's
long-acting protein programs, which are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Investors
are cautioned that forward-looking statements involve risks and uncertainties
that may affect PROLOR's business and prospects, including the risks that
PROLOR may not succeed in generating any revenues or developing any commercial
products, including any long-acting versions of human growth hormone,
erythropoietin, interferon beta, GLP-1 and other products; that the
long-acting products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would support the
approval or marketing of these products for the indications being studied or
for other indications; that ongoing studies may not continue to show
substantial or any activity; that the actual dollar amount of any grants from
Israel's Office of the Chief Scientist is uncertain and is subject to policy
changes of the Israeli government, and that such grants may be insufficient to
assist with product development; and other risks and uncertainties that may
cause results to differ materially from those set forth in the forward-looking
statements. The results of clinical trials in humans may produce results that
differ significantly from the results of clinical and other trials in animals.
The results of early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products using the
CTP platform technology could also be affected by a number of other factors,
including unexpected safety, efficacy or manufacturing issues, additional time
requirements for data analyses and decision making, the impact of
pharmaceutical industry regulation, the impact of competitive products and
pricing and the impact of patents and other proprietary rights held by
competitors and other third parties. In addition to the risk factors
described above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in PROLOR's filings
with the Securities and Exchange Commission. The forward-looking statements
contained in this press release speak only as of the date the statements were
made, and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.

PROLOR CONTACT:                MEDIA CONTACT:
Shai Novik, President          Barbara Lindheim
PROLOR Biotech, Inc.           BLL Partners, LLC
Tel: +1 866 644-7811           +1 212 584-2276
Email: shai@prolor-biotech.com blindheim@bllbiopartners.com

SOURCE PROLOR Biotech, Inc.

Website: http://www.prolor-biotech.com
 
Press spacebar to pause and continue. Press esc to stop.